Unusual 11 Mid-Day Movers 03/26: (ISR) (KERX) (FFHL) Higher; (EXEL) (BODY) (REED) Lower
Exelixis, Inc. (Nasdaq: EXEL) 36.3% LOWER; announced that the Independent Data Monitoring Committee (IDMC) notified the company today that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014.
Body Central Corp. (Nasdaq: BODY) 34.5% LOWER; reported Q4 EPS of ($0.74), $0.41 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $66.2 million versus the consensus estimate of $72.66 million. Store sales decreased 19.5% to $59.4